Ashwagen® shows efficacy in managing stress and anxiety in hypertensive patients
A Phase III trial demonstrated that Ashwagen® significantly reduced anxiety and stress markers in patients with hypertension.
Therapeutic Area
Therapeutic area intelligence for Stress and Anxiety with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.